icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
UBSpWdjEnnTAByrz
Listen
